114.76
price up icon0.46%   0.53
after-market After Hours: 113.66 -1.10 -0.96%
loading
Gilead Sciences Inc stock is traded at $114.76, with a volume of 5.81M. It is up +0.46% in the last 24 hours and up +3.51% over the past month. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$114.23
Open:
$114.27
24h Volume:
5.81M
Relative Volume:
0.74
Market Cap:
$142.75B
Revenue:
$28.73B
Net Income/Loss:
$5.97B
P/E Ratio:
24.16
EPS:
4.75
Net Cash Flow:
$9.84B
1W Performance:
+1.06%
1M Performance:
+3.51%
6M Performance:
+18.37%
1Y Performance:
+47.03%
1-Day Range:
Value
$113.53
$115.75
1-Week Range:
Value
$112.30
$117.60
52-Week Range:
Value
$72.43
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,600
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
114.76 140.60B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
760.08 725.47B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.26 400.31B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
189.31 333.00B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.63 224.91B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
81.75 211.08B 63.92B 17.43B 17.04B 6.87

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-25-25 Upgrade Needham Hold → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
09:25 AM

Gilead files covid 19 remdesivir actions against Chinese military research institute - IAM Patent

09:25 AM
pulisher
09:00 AM

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance

09:00 AM
pulisher
04:30 AM

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

04:30 AM
pulisher
Jul 29, 2025

NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360

Jul 29, 2025
pulisher
Jul 29, 2025

Gilead Sciences’ TAF Study in Children with Hepatitis B: An Update - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma

Jul 29, 2025
pulisher
Jul 29, 2025

Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Gilead price collects profitsForecast today29-07-2025 - Economies.com

Jul 29, 2025
pulisher
Jul 29, 2025

Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com

Jul 29, 2025
pulisher
Jul 29, 2025

Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Why Gilead Sciences Stock Slipped Today - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits

Jul 28, 2025
pulisher
Jul 28, 2025

Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily

Jul 28, 2025
pulisher
Jul 28, 2025

TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 27, 2025

What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st

Jul 27, 2025
pulisher
Jul 27, 2025

Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu

Jul 27, 2025
pulisher
Jul 26, 2025

Gilead Sciences Stock Surges Amid Promising Trials - TipRanks

Jul 26, 2025
pulisher
Jul 26, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences Stock Just Popped - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead upgraded to Buy at Needham on new HIV drug - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener

Jul 25, 2025
pulisher
Jul 25, 2025

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org

Jul 25, 2025
pulisher
Jul 25, 2025

Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Why Gilead Sciences Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - beatles.ru

Jul 24, 2025

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general PFE
$23.81
price down icon 2.02%
$301.37
price down icon 0.72%
drug_manufacturers_general SNY
$49.25
price down icon 0.20%
drug_manufacturers_general NVO
$50.03
price down icon 7.25%
drug_manufacturers_general MRK
$81.75
price down icon 1.06%
Cap:     |  Volume (24h):